Raffles Medical May Benefit From Singapore's Value-Unlocking Policy Initiatives -- Market Talk

Dow Jones

Nov 04, 2025

0215 GMT - Raffles Medical Group is likely a key beneficiary of Singapore's value-unlocking policy initiatives aimed at enhancing market efficiency and liquidity, RHB Research's Shekhar Jaiswal says. Its inclusion in the 'iEdge Singapore Next 50 Index' should further boost institutional visibility and passive inflows, the analyst says in a note. Also, the healthcare provider has signed a memorandum of understanding with Vietnam-based Gene Solutions to facilitate pharmaceutical-sponsored clinical trials across Southeast Asia, enhancing its precision medicine capabilities. RHB Research upgrades the stock's rating to buy from neutral and raises the target price to S$1.15 from S$1.10 after rolling forward the valuation base year. Shares are 0.5% higher at S$0.995. (ronnie.harui@wsj.com)

(END) Dow Jones Newswires

November 03, 2025 21:15 ET (02:15 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580327960"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580327960\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580327960?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 10:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580327960","market":"nz","top_or_hot":-1,"title":"Raffles Medical May Benefit From Singapore's Value-Unlocking Policy Initiatives -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0215 GMT - Raffles Medical Group is likely a key beneficiary of Singapore's value-unlocking policy initiatives aimed at enhancing market efficiency and liquidity, RHB Research's Shekhar Jaiswal says. Its inclusion in the 'iEdge Singapore Next 50 Index' should further boost institutional visibility and passive inflows, the analyst says in a note. Also, the healthcare provider has signed a memorandum of understanding with Vietnam-based Gene Solutions to facilitate pharmaceutical-sponsored clinical trials across Southeast Asia, enhancing its precision medicine capabilities. RHB Research upgrades the stock's rating to buy from neutral and raises the target price to S$1.15 from S$1.10 after rolling forward the valuation base year. Shares are 0.5% higher at S$0.995. (ronnie.harui@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 21:15 ET (02:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Raffles Medical May Benefit From Singapore's Value-Unlocking Policy Initiatives -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRaffles Medical May Benefit From Singapore's Value-Unlocking Policy Initiatives -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-04 10:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0215 GMT - Raffles Medical Group is likely a key beneficiary of Singapore's value-unlocking policy initiatives aimed at enhancing market efficiency and liquidity, RHB Research's Shekhar Jaiswal says. Its inclusion in the 'iEdge Singapore Next 50 Index' should further boost institutional visibility and passive inflows, the analyst says in a note. Also, the healthcare provider has signed a memorandum of understanding with Vietnam-based Gene Solutions to facilitate pharmaceutical-sponsored clinical trials across Southeast Asia, enhancing its precision medicine capabilities. RHB Research upgrades the stock's rating to buy from neutral and raises the target price to S$1.15 from S$1.10 after rolling forward the valuation base year. Shares are 0.5% higher at S$0.995. (ronnie.harui@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 21:15 ET (02:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6511","symbol_name":"医疗保健服务概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2580327960","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580327960","pubTimestamp":1762222500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0215 GMT - Raffles Medical Group is likely a key beneficiary of Singapore's value-unlocking policy initiatives aimed at enhancing market efficiency and liquidity, RHB Research's Shekhar Jaiswal says. Its inclusion in the 'iEdge Singapore Next 50 Index' should further boost institutional visibility and passive inflows, the analyst says in a note. Also, the healthcare provider has signed a memorandum of understanding with Vietnam-based Gene Solutions to facilitate pharmaceutical-sponsored clinical trials across Southeast Asia, enhancing its precision medicine capabilities. RHB Research upgrades the stock's rating to buy from neutral and raises the target price to S$1.15 from S$1.10 after rolling forward the valuation base year. Shares are 0.5% higher at S$0.995. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6511":"医疗保健服务概念","BSL.SI":"莱佛士医疗","BK6092":"保健护理机构"},"translate_title":"莱佛士医疗可能受益于新加坡的价值释放政策举措——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSL.SI":1.5},"content_text":"0215 GMT - Raffles Medical Group is likely a key beneficiary of Singapore's value-unlocking policy initiatives aimed at enhancing market efficiency and liquidity, RHB Research's Shekhar Jaiswal says. Its inclusion in the 'iEdge Singapore Next 50 Index' should further boost institutional visibility and passive inflows, the analyst says in a note. Also, the healthcare provider has signed a memorandum of understanding with Vietnam-based Gene Solutions to facilitate pharmaceutical-sponsored clinical trials across Southeast Asia, enhancing its precision medicine capabilities. RHB Research upgrades the stock's rating to buy from neutral and raises the target price to S$1.15 from S$1.10 after rolling forward the valuation base year. Shares are 0.5% higher at S$0.995. (ronnie.harui@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 03, 2025 21:15 ET (02:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}